Nano-engineering of ketorolac tromethamine platforms for ocular treatment of inflammatory disorders

Nanomedicine (Lond). 2021 Feb;16(5):401-414. doi: 10.2217/nnm-2020-0403. Epub 2021 Feb 15.

Abstract

Aim: The development and optimization of Ketorolac tromethamine-loaded polylactic-co-glycolic acid nanoparticles (KT-NPs) for the treatment of inflammatory processes of the eye. Materials & methods: KT-NPs were developed by factorial design and characterized by assessing their physicochemical properties. Biopharmaceutical behavior studies, ocular tolerance, anti-inflammatory efficacy and bioavailability tests were performed on pigs. Results: Optimized KT-NPs of 112 nm, narrow distribution with encapsulation efficiency near 100% were obtained. KT release followed the Weibull model and there was significantly greater retention in the cornea and sclera than in the commercial reference. KT-NPs showed no signs of ocular irritancy and similar anti-inflammatory efficacy to the commercial reference. Conclusion: KT-NPs were a suitable alternative for the treatment of inflammatory disorders of the anterior and posterior segments of the eye as an alternative to conventional topical formulations.

Keywords: anti-inflammatory efficacy; factorial design; ketorolac tromethamine; nanoparticles; ocular administration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Ophthalmic
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal
  • Biological Availability
  • Ketorolac Tromethamine
  • Nanoparticles*
  • Swine

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Ketorolac Tromethamine